​Small: National Nanoscience Center builds personalized multifunctional tumor in situ vaccine based on natural nanomaterials

After the tumor tissue is destroyed by physical methods (such as photothermal therapy, radiation therapy, cryoablation, radiofrequency ablation, etc.

Tumor vaccines have become a hot field in the fight against cancer

In response to the above key issues in tumor vaccine research, Zhao Xiao's research team from the National Center for Nanoscience and Technology published a paper entitled: Antigen Capture and Immune Modulation by Bacterial Outer Membrane Vesicles as In Situ in Wiley's flagship journal Small (IF=13.

The vaccine system can not only enhance the efficiency of antigen recognition and processing, but also realize the reactivation of the immunosuppressive microenvironment, enhance immune-mediated tumor clearance after photothermal therapy (PTT), and provide a new technology for the development of personalized tumor vaccines support

Vaccine design ideas and mechanism of action after PTT

Given the time required for antigen release after photothermal therapy (PTT) ablation, the research team employed a two-step treatment strategy to improve synergistic immunotherapy after PTT

Overall, the OMV-based in situ vaccine with antigen capture and immunomodulatory functions developed in this study provides a promising strategy for the combination of topical therapy and immunotherapy

The National Nanoscience Center team has long been committed to using nanotechnology to design and develop different types of vaccine carriers

Original source:

Yao Li, Kaiyue Zhang, Yao Wu, et al.